Zhixin Haozheng
智新浩正
Zhixin Haozheng
Biotech/Healthcare
Zhixin Haozheng develops regenerative islet technologies focused on the in vitro regeneration of human tissues and organs. Its lead pipeline is regenerative islets for transplantation to treat diabetes.
Latest round: Pre Series A (2022)
Source: ChinaBulls — chinabulls.com
Last updated 2022-11-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.